The results also show that RK-33 slowed down tumor progression across all three BL models, but that Pevonedistat proved more effective which suggests the cell lines developed alternative survival mechanisms against DDX3X inhibition in vivo. This evidence concerns the gene DDX3X and Burkitt lymphoma.